Semaglutide
The Gold Standard in Medical Weight Loss.
What It Treats
How It Works
Semaglutide is a GLP-1 receptor agonist — it mimics the incretin hormone GLP-1 to reduce appetite centrally in the brain, slow gastric emptying, and enhance insulin sensitivity. Weekly subcutaneous injection with gradual dose titration.
Mechanism of Action
Semaglutide mimics GLP-1, a hormone your gut releases after eating. But here's why it works so much better than willpower alone: it acts on three systems simultaneously. In the brain, it reduces appetite signals in the hypothalamus — you genuinely feel less hungry. In the stomach, it slows gastric emptying so food stays longer and you feel full sooner. And in the pancreas, it improves insulin signaling so your body processes glucose more efficiently instead of storing it as fat. The STEP 1 trial in the New England Journal of Medicine showed participants lost an average of 14.9% of their body weight over 68 weeks — results previously only achievable through bariatric surgery.
In 1,961 adults with BMI 30+ (or 27+ with comorbidities), semaglutide 2.4mg weekly produced a mean body weight reduction of 14.9% vs 2.4% with placebo over 68 weeks. 86.4% of semaglutide participants achieved at least 5% weight loss, and 69.1% achieved at least 10%. Gastrointestinal events were the most common adverse effects, mostly mild-to-moderate and transient.
Over 104 weeks of continuous treatment, semaglutide 2.4mg produced sustained weight loss of 15.2% vs 2.6% with placebo. Participants maintained clinically meaningful improvements in waist circumference, blood pressure, HbA1c, and lipid profiles throughout the 2-year period. The study confirmed that semaglutide delivers durable weight loss when continued long-term.
The Results
The clinical data speaks for itself. In the STEP 5 trial — a 2-year study published in Nature Medicine — participants maintained 15.2% body weight loss at 104 weeks with continued treatment. But it's not just about the scale: the SELECT cardiovascular outcomes trial, the largest of its kind, showed a 20% reduction in major cardiovascular events (heart attack, stroke, cardiovascular death) in patients taking semaglutide. This is why the medical community considers semaglutide a breakthrough — it treats obesity as the metabolic disease it is, not just a cosmetic concern.
In 17,604 adults aged 45+ with established cardiovascular disease and BMI 27+, semaglutide 2.4mg weekly reduced the risk of major adverse cardiovascular events (MACE) by 20% compared to placebo over a median follow-up of 39.8 months. This landmark trial established semaglutide as the first obesity medication to demonstrate cardiovascular event reduction — shifting obesity treatment from cosmetic to disease-modifying.
Ideal For
Adults with BMI 30+ (or 27+ with weight-related conditions) who want significant, sustained weight loss with cardiovascular benefits. Also effective for patients who have plateaued with diet and exercise alone.
Your Protocol
Weekly subcutaneous injection. Start at 0.25mg/week for 4 weeks, titrate up every 4 weeks through 0.5mg, 1.0mg, 1.7mg to maintenance dose of 2.4mg/week. Most patients reach full dose by week 16-20.
Ready to Start Semaglutide?
Add to your plan and bundle with other services to save 15%. Or book directly.
Cancellation Policy: A $50 non-refundable deposit is required to confirm your appointment for all consultations — our front desk will reach out to collect it after you book. The deposit is applied toward your visit cost. We require at least 24 hours' notice for cancellations or changes. No-shows or late cancellations will forfeit the deposit. By booking, you agree to these terms.
Business hours: Mon–Thu 8am–6pm · Fri 8am–12pm
